A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-24 and is reviewed periodically as new material appears.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Fibrodysplasia ossificans progressiva (; abbr. FOP), also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease. Fibrous connective tissue such as muscle, tendons, and ligaments ossify into bone tissue. The condition ultimately immobilises sufferers, as new bone replaces musculature and fuses with the existing skeleton. This has earned FOP the nickname "stone man disease". FOP is caused by a mutation of the gene ACVR1, affecting the body's repair mechanism. Fibrous tissue, including muscle, tendons, and ligaments ossify, either spontaneously or when damaged by trauma. In many cases, otherwise minor injuries can cause joints to permanently fuse as new bone forms, replacing the damaged muscle tissue. This new bone formation (known as "heterotopic ossification") eventually forms a secondary skeleton progressively restricting the patient's ability to move. Circumstantial evidence suggests that the disease can cause joint degradation separate from its characteristic bone growth. It is a severe, debilitating disorder. Bone formed as a result of ossification is identical to "normal" bone, but in improper locations. The rate of ossified bone growth varies by patient. It is the only known medical condition in which tissue of one organ system changes into that of another. Surgical removal of ossified bone causes the body to "repair" the affected area with additional bone. FOP has no current known cure. However, there are intermittent treatments such as anti-inflammatory drugs.
=== Primary treatment === Primary treatment aims to remove ions, dissolved gasses, and organic contaminants from pre-treated water. In the 21st century, multiple-pass reverse osmosis is often the primary method used during this step to remove dissolved ions and dissolved organic solids. As a membrane-filtration method it also removes suspended solids as well. Reverse osmosis is often used in this step to remove both dissolved ions and dissolved organic material. Dissolved gases, including oxygen and volatile organic compounds, are removed during primary treatment by vacuum degassing or membrane degassing. Vacuum degassing towers were more common historically, but newer systems have trended towards used of membrane degasification. Ultraviolet (UV) light can used to sterilize purified water during primary treatment though UV treatment can also be left until the polishing stage.
== Cast == Karl Urban as Dredd: A famed and feared Judge. Producer Allon Reich described Dredd as "an extreme character, and he administers justice with an extreme lack of prejudice". Urban approached the producers about joining the film. He found the role challenging because the character never removes his helmet, requiring Urban to convey emotion without using his eyes. He viewed the character as an average man with an insanely tough job in a fragmenting society and likened Dredd's heroism to that of a fireman. The role also demanded physical preparation; Urban undertook intensive physical training to become a "beast of a man". He also underwent weapons and technical training to learn how to operate under fire, arrest criminals and breach doors. He insisted on performing his own motorcycle stunts for the film. He played Dredd with a raspy and harsh vocal tone akin to "a saw cutting through bone", which he found difficult to sustain.
having an acceptable treatment protocol in place that changes the outcome for patients diagnosed early with the disease an understanding of the condition's natural history an understanding about who will be treated as a patient a screening test that is reliable for both affected and unaffected patients and is acceptable to the public As diagnostic techniques have progressed, debates have arisen as to how screening programs should adapt. Tandem mass spectrometry has greatly expanded the potential number of diseases that can be detected, even without satisfying all of the other criteria used for making screening decisions. Duchenne muscular dystrophy is a disease that has been added to screening programs in several jurisdictions around the world, despite the lack of evidence as to whether early detection improves the clinical outcome for a patient.
Sources: en.wikipedia.org
Directed by Agnieszka Holland, it is a fictionalized account of the same-sex relationship between Arthur Rimbaud (DiCaprio) and Paul Verlaine (David Thewlis). DiCaprio was cast when River Phoenix died before filming began. Although the film failed commercially, it has been included in the catalog of the Warner Archive Collection, which releases classic and cult films from Warner Bros.' library on home video. A review in the San Francisco Chronicle called DiCaprio "his generation's great acting promise" but criticized the mismatch between Thewlis's "cultivated" British accent and DiCaprio's "Southern California twang". DiCaprio next starred opposite Claire Danes in Baz Luhrmann's Romeo + Juliet (1996), an abridged modernization of William Shakespeare's romantic tragedy, which retained the original Shakespearean dialogue. DiCaprio was initially unsure about another Romeo and Juliet adaptation, but at his father's suggestion, he agreed to examine Luhrmann's work more closely. DiCaprio and Luhrmann then spent a two-week workshop exchanging ideas, which led to the collaboration. Romeo + Juliet established DiCaprio as a leading Hollywood actor; according to film scholar Murray Pomerance, DiCaprio's newfound popularity helped the film become profitable only days after its release. Reviewing DiCaprio's early works, David Thomson of The Guardian called DiCaprio "a revelation" in What's Eating Gilbert Grape, "very moving" in This Boy's Life, "suitably desperate" in The Basketball Diaries and "a vital spark" in Romeo + Juliet.
== Emergencies == As the complete cross-matching process takes approximately 1 hour, it is not always used in emergencies. In the case of an emergency, a type-specific blood to which the recipient has no antibodies, can be requested. It is thought that this lifesaving measure is of more benefit than any risk of an antibody-mediated transfusion reaction. This type of blood has less risk of a serious transfusion reaction because it is both ABO compatible and Rhesus (Rh)-compatible. Universal donor blood, which is both type O and Rh negative, can be given if the recipient's blood group is not known, as may happen in an emergency. It is the policy of some institutions to reserve the releasing of O− blood only for female patients of childbearing age. This serves two purposes. First, it preserves the lower stock of O− blood and secondly, this eliminates the risk of O− negative mothers forming anti-D (Rh) antibodies from exposure to O+ blood. Anti-D (Rh) can cross the placenta during pregnancy and attack an unborn child's RBCs if they are D (Rh) positive causing haemolytic disease of the newborn. In an emergency, blood grouping can be done easily and quickly in 2 or 3 minutes in the laboratory on glass slides with appropriate reagents, by trained technical staff. This method depends on the presence or absence of agglutination (clumping of red blood cells), which can usually be visualized directly. Presence of agglutination indicates incompatibility. Occasionally a light microscope may be needed.
=== President and Past Presidents (since 1953) === 2022–2024 Julia Laskin 2020–2022 Susan Richardson 2016–2018 Vicki Wysocki 2014–2016 Jennifer Brodbelt 2012–2014 Susan Weintraub 2006–2008 Barbara S. Larsen 2002–2004 Catherine E. Costello 1996–1998 Veronica M. Bierbaum 1982–1984 Catherine Fenselau
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines. It is given by subcutaneous injection (injection under the skin). The most common side effect is pain and redness at the site of injection. Other side effects include allergic reactions. It is a calcitonin gene-related peptide antagonist. It was approved for medical use in the United States in 2018, the European Union in 2019, the United Kingdom in 2020, and Argentina by September 2021.
Eating much faster than normal, perhaps in a short space of time Eating until feeling uncomfortably full Eating a large amount even when not hungry Subjective loss of control over how much or what is eaten Planning and allocating specific times for bingeing Eating alone or secretly Not being able to remember what was eaten after the binge Feelings of guilt, shame, or disgust following a food binge Body image disturbance In contrast to bulimia nervosa, binge eating episodes are not regularly followed by activities intended to compensate for the amount of food consumed, such as self-induced vomiting, laxative or enema misuse, or strenuous exercise. BED is characterized more by overeating than dietary restriction. Those with BED often have poor body image and frequently diet, but are unsuccessful due to the severity of their binge eating. Obesity is common in persons with BED, as are depression, low self-esteem, stress and boredom. Regarding cognitive abilities, individuals showing severe binge eating symptoms may experience small dysfunctions in executive functions. Those with BED are also at risk of non-alcoholic fatty liver disease, menstrual irregularities such as amenorrhea, and gastrointestinal problems such as acid reflux and heartburn.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.